Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Article

MAGE-A3 is highly expressed in a subset of colorectal cancer patients

HMC Shantha Kumara, Michael J. Grieco, Otavia L. Caballero, Tao Su, Aqeel Ahmed, Erika Ritter, Sacha Gnjatic, Vesna Cekic, Lloyd J. Old, Andrew J. Simpson, Carlos Cordon-Cardo and Richard L. Whelan
HMC Shantha Kumara
1Division of Colon and Rectal Surgery, Department of Surgery, St. Luke’s-Roosevelt Hospital Center, New York, NY 10019, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael J. Grieco
1Division of Colon and Rectal Surgery, Department of Surgery, St. Luke’s-Roosevelt Hospital Center, New York, NY 10019, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Otavia L. Caballero
2Ludwig Collaborative Laboratory for Cancer Biology and Therapy, Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tao Su
3Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aqeel Ahmed
3Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erika Ritter
4Ludwig Institute for Cancer Research, New York Branch of Human Cancer Immunology at Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sacha Gnjatic
4Ludwig Institute for Cancer Research, New York Branch of Human Cancer Immunology at Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vesna Cekic
1Division of Colon and Rectal Surgery, Department of Surgery, St. Luke’s-Roosevelt Hospital Center, New York, NY 10019, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lloyd J. Old
4Ludwig Institute for Cancer Research, New York Branch of Human Cancer Immunology at Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew J. Simpson
4Ludwig Institute for Cancer Research, New York Branch of Human Cancer Immunology at Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlos Cordon-Cardo
3Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard L. Whelan
1Division of Colon and Rectal Surgery, Department of Surgery, St. Luke’s-Roosevelt Hospital Center, New York, NY 10019, USA
5Section of Colon and Rectal Surgery, Department of Surgery, New York-Presbyterian Hospital, Columbia University, New York, NY 10032, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rlw3@columbia.edu
DOI:  Published January 2012
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

The expression of Cancer/Testis (CT) antigens in some tumors and restricted expression in normal tissue make CT antigens attractive vaccine targets. We evaluated the expression of MAGE-A3, PLAC1, GAGE, and CTAG2 in a series of colorectal cancers (CRC). CT mRNA expression was determined via quantitative PCR on paired tumors and normal tissue samples from 82 CRC patients. In addition, plasma antibody titers specific to MAGE-A3, PLAC1, GAGE, and CTAG2 were determined via ELISA. Tissue expression of MAGE-A3 was assessed via a standard IHC protocol. The Student’s t-test was used for statistical analysis (significance p < 0.05). Tumor expression of MAGE-A3, CTAG2, and GAGE was compared to the levels of expression in testis. The percentage of samples that had a tumor vs. testis expression ratio above 0.1% was: MAGE-A3 (28%) and CTAG2 (17%) but no tumor presented GAGE expression levels above 0.1%. The expression levels of PLAC1 in tumors were compared to the levels in placenta, and in 12.8% of the samples analyzed, these levels were above 0.1%. Sero-reactivity specific for MAGE-A genes and PLAC1 was noted in 2.4% and 2.6% of patients, respectively. MAGE-A3 and PLAC1 may hold promise as vaccine targets for CRC. Further study is warranted.

This article was published in Cancer Immunity, a Cancer Research Institute journal that ceased publication in 2013 and is now provided online in association with Cancer Immunology Research.

  • Copyright © 2012 by Richard L. Whelan
View Full Text
PreviousNext
Back to top
Cancer Immunity Archive: 12 (2)
January 2012
Volume 12, Issue 2
  • Table of Contents

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
MAGE-A3 is highly expressed in a subset of colorectal cancer patients
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
MAGE-A3 is highly expressed in a subset of colorectal cancer patients
HMC Shantha Kumara, Michael J. Grieco, Otavia L. Caballero, Tao Su, Aqeel Ahmed, Erika Ritter, Sacha Gnjatic, Vesna Cekic, Lloyd J. Old, Andrew J. Simpson, Carlos Cordon-Cardo and Richard L. Whelan
Cancer Immun January 1 2012 (12) (2) 16;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
MAGE-A3 is highly expressed in a subset of colorectal cancer patients
HMC Shantha Kumara, Michael J. Grieco, Otavia L. Caballero, Tao Su, Aqeel Ahmed, Erika Ritter, Sacha Gnjatic, Vesna Cekic, Lloyd J. Old, Andrew J. Simpson, Carlos Cordon-Cardo and Richard L. Whelan
Cancer Immun January 1 2012 (12) (2) 16;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Results
    • Discussion
    • Materials and methods
    • Acknowledgments
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement